Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: multiple sclerosis therapies - Provid

Next Previous
X
Search
Drug Profile

Research programme: multiple sclerosis therapies - Provid

Alternative Names: PV-072; PV-267

Latest Information Update: 04 Nov 2017

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Provid Pharmaceuticals
  • Developer Provid Pharmaceuticals; University of Texas Health Science Center at San Antonio
  • Class Small molecules
  • Mechanism of Action HLA-DR antigen inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Multiple sclerosis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Multiple-sclerosis in USA
  • 15 Oct 2013 Preclinical development is ongoing in USA
  • 14 Jan 2004 Provid and Suntory have entered into an agreement to co-develop small peptide mimetic inhibitors of antigen presentation by MHC class II DR2 molecules in the US for multiple sclerosis

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top